Indian IPR think tank ticks all the wrong boxes?
This article was originally published in Scrip
The wrong people, poor timing, conflict of interest and seemingly excessive authority are some of the strong allegations being made against an Indian government constituted think tank which is expected to draft the country's intellectual property rights (IPR) policy.
You may also be interested in...
Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…
Eisai and partner Sun to take lorcaserin off the Indian market. It remains to be seen whether the Japanese firm sees merit in pursuing a simmering patent infringement suit against Dr Reddy’s, which may need to review its own plans for lorcaserin.